{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,22]],"date-time":"2026-11-22T06:40:55Z","timestamp":1795329655293,"version":"4.10.3"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T00:00:00Z","timestamp":1541721600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1038\/s41416-018-0328-y","type":"journal-article","created":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T12:32:13Z","timestamp":1541766733000},"page":"6-15","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1127,"title":["Cytokines in clinical cancer immunotherapy"],"prefix":"10.1038","volume":"120","author":[{"given":"Pedro","family":"Berraondo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel F.","family":"Sanmamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda C","family":"Ochoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u00f1aki","family":"Etxeberria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Aznar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"P\u00e9rez-Gracia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda E.","family":"Rodr\u00edguez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Ponz-Sarvise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Casta\u00f1\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Melero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,9]]},"reference":[{"key":"328_CR1","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1098\/rspb.1957.0048","volume":"147","author":"A Isaacs","year":"1957","unstructured":"Isaacs, A. & Lindenmann, J. Virus interference. I. The interferon. Proc. R. Soc. Lond. Ser. B Biol. Sci. 147, 258\u2013267 (1957).","journal-title":"Proc. R. Soc. Lond. Ser. B Biol. Sci."},{"key":"328_CR2","first-page":"365","volume":"45","author":"I Gresser","year":"1970","unstructured":"Gresser, I. & Bourali, C. Antitumor effects of interferon preparations in mice. J. Natl. Cancer Inst. 45, 365\u2013376 (1970).","journal-title":"J. Natl. Cancer Inst."},{"key":"328_CR3","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","volume":"13","author":"G Fyfe","year":"1995","unstructured":"Fyfe, G. et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13, 688\u2013696 (1995).","journal-title":"J. Clin. Oncol."},{"key":"328_CR4","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","volume":"17","author":"MB Atkins","year":"1999","unstructured":"Atkins, M. B. et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105\u20132116 (1999).","journal-title":"J. Clin. Oncol."},{"key":"328_CR5","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1200\/JCO.1986.4.6.900","volume":"4","author":"HM Golomb","year":"1986","unstructured":"Golomb, H. M. et al. Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients. J. Clin. Oncol. 4, 900\u2013905 (1986).","journal-title":"J. Clin. Oncol."},{"key":"328_CR6","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1056\/NEJM199311253292203","volume":"329","author":"P Solal-Celigny","year":"1993","unstructured":"Solal-Celigny, P. et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. New Engl. J. Med. 329, 1608\u20131614 (1993).","journal-title":"New Engl. J. Med."},{"key":"328_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","volume":"14","author":"JM Kirkwood","year":"1996","unstructured":"Kirkwood, J. M. et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 14, 7\u201317 (1996).","journal-title":"J. Clin. Oncol."},{"key":"328_CR8","doi-asserted-by":"publisher","first-page":"671","DOI":"10.7326\/0003-4819-100-5-671","volume":"100","author":"JE Groopman","year":"1984","unstructured":"Groopman, J. E. et al. Recombinant alpha-2 interferon therapy for Kaposi\u2019s sarcoma associated with the acquired immunodeficiency syndrome. Ann. Intern. Med. 100, 671\u2013676 (1984).","journal-title":"Ann. Intern. Med."},{"key":"328_CR9","doi-asserted-by":"publisher","unstructured":"Waldmann, T. A. Cytokines in cancer immunotherapy. Cold Spring Harb. Perspect. Biol. \n                    https:\/\/doi.org\/10.1101\/cshperspect.a028472\n                    \n                   (2017).","DOI":"10.1101\/cshperspect.a028472"},{"key":"328_CR10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56\u201361 (2015).","journal-title":"Science"},{"key":"328_CR11","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"J Haanen","year":"2017","unstructured":"Haanen, J. et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 28, iv119\u2013iv142 (2017).","journal-title":"Ann. Oncol."},{"key":"328_CR12","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer, R. J. et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. New Engl. J. Med. 378, 1277\u20131290 (2018).","journal-title":"New Engl. J. Med."},{"key":"328_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. New Engl. J. Med. 373, 23\u201334 (2015).","journal-title":"New Engl. J. Med."},{"key":"328_CR14","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","volume":"36","author":"MJ Overman","year":"2018","unstructured":"Overman, M. J. et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer. J. Clin. Oncol. 36, 773\u2013779 (2018).","journal-title":"J. Clin. Oncol."},{"key":"328_CR15","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrc3973","volume":"15","author":"I Melero","year":"2015","unstructured":"Melero, I. et al. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat. Rev. Cancer 15, 457\u2013472 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"328_CR16","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June, C. H., O\u2019Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR T cell immunotherapy for human cancer. Science 359, 1361\u20131365 (2018).","journal-title":"Science"},{"key":"328_CR17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/imr.12132","volume":"257","author":"CS Hinrichs","year":"2014","unstructured":"Hinrichs, C. S. & Rosenberg, S. A. Exploiting the curative potential of adoptive T cell therapy for cancer. Immunol. Rev. 257, 56\u201371 (2014).","journal-title":"Immunol. Rev."},{"key":"328_CR18","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","volume":"15","author":"M Chmielewski","year":"2015","unstructured":"Chmielewski, M. & Abken, H. TRUCKs: the fourth generation of CARs. Expert Opin. Biol. Ther. 15, 1145\u20131154 (2015).","journal-title":"Expert Opin. Biol. Ther."},{"key":"328_CR19","doi-asserted-by":"publisher","first-page":"5051","DOI":"10.4049\/jimmunol.171.10.5051","volume":"171","author":"C Jackaman","year":"2003","unstructured":"Jackaman, C. et al. IL-2 intratumoral immunotherapy enhances CD8+T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J. Immunol. 171, 5051\u20135063 (2003).","journal-title":"J. Immunol."},{"key":"328_CR20","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1200\/JCO.2004.04.059","volume":"22","author":"B Sangro","year":"2004","unstructured":"Sangro, B. et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J. Clin. Oncol. 22, 1389\u20131397 (2004).","journal-title":"J. Clin. Oncol."},{"key":"328_CR21","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1158\/1078-0432.CCR-17-1365","volume":"24","author":"J Hu","year":"2018","unstructured":"Hu, J. et al. T cell homing therapy for reducing regulatory T cells and preserving effector T cell function in large solid tumors. Clin. Cancer Res. 24, 2920\u20132934 (2018).","journal-title":"Clin. Cancer Res."},{"key":"328_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1\u201310 (2013).","journal-title":"Immunity"},{"key":"328_CR23","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 541, 321\u2013330 (2017).","journal-title":"Nature"},{"key":"328_CR24","doi-asserted-by":"publisher","first-page":"4254","DOI":"10.4049\/jimmunol.1401109","volume":"193","author":"RM Spaapen","year":"2014","unstructured":"Spaapen, R. M. et al. Therapeutic activity of high-dose intratumoral IFN-beta requires direct effect on the tumor vasculature. J. Immunol. 193, 4254\u20134260 (2014).","journal-title":"J. Immunol."},{"key":"328_CR25","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1634\/theoncologist.2012-0123","volume":"17","author":"TM Herndon","year":"2012","unstructured":"Herndon, T. M. et al. U.S. Food and Drug Administration Approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma. Oncologist 17, 1323\u20131328 (2012).","journal-title":"Oncologist"},{"key":"328_CR26","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1158\/1078-0432.CCR-10-1114","volume":"17","author":"S Hervas-Stubbs","year":"2011","unstructured":"Hervas-Stubbs, S. et al. Direct effects of type I interferons on cells of the immune system. Clin. Cancer Res. 17, 2619\u20132627 (2011).","journal-title":"Clin. Cancer Res."},{"key":"328_CR27","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1002\/hep.24306","volume":"53","author":"J Fioravanti","year":"2011","unstructured":"Fioravanti, J. et al. Anchoring interferon alpha to apolipoprotein A-I reduces hematological toxicity while enhancing immunostimulatory properties. Hepatology 53, 1864\u20131873 (2011).","journal-title":"Hepatology"},{"key":"328_CR28","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.4049\/jimmunol.1101598","volume":"188","author":"J Fioravanti","year":"2012","unstructured":"Fioravanti, J. et al. The fusion protein of IFN-alpha and apolipoprotein A-I crosses the blood-brain barrier by a saturable transport mechanism. J. Immunol. 188, 3988\u20133992 (2012).","journal-title":"J. Immunol."},{"key":"328_CR29","doi-asserted-by":"publisher","first-page":"5247","DOI":"10.18632\/oncotarget.14127","volume":"8","author":"M Vasquez","year":"2017","unstructured":"Vasquez, M. et al. Antitumor effect of an adeno-associated virus expressing apolipoprotein A-1 fused to interferon alpha in an interferon alpha-resistant murine tumor model. Oncotarget 8, 5247\u20135255 (2017).","journal-title":"Oncotarget"},{"key":"328_CR30","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1158\/0008-5472.CAN-17-1980","volume":"78","author":"A Cauwels","year":"2018","unstructured":"Cauwels, A. et al. Delivering type I interferon to dendritic cells empowers tumor eradication and immune combination treatments. Cancer Res. 78, 463\u2013474 (2018).","journal-title":"Cancer Res."},{"key":"328_CR31","doi-asserted-by":"publisher","first-page":"e1398876","DOI":"10.1080\/2162402X.2017.1398876","volume":"7","author":"A Cauwels","year":"2018","unstructured":"Cauwels, A. et al. A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment. Oncoimmunology 7, e1398876 (2018).","journal-title":"Oncoimmunology"},{"key":"328_CR32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ccr.2013.12.004","volume":"25","author":"X Yang","year":"2014","unstructured":"Yang, X. et al. Targeting the tumor microenvironment with interferon-beta bridges innate and adaptive immune responses. Cancer Cell 25, 37\u201348 (2014).","journal-title":"Cancer Cell"},{"key":"328_CR33","doi-asserted-by":"publisher","first-page":"e0179431","DOI":"10.1371\/journal.pone.0179431","volume":"12","author":"D Charych","year":"2017","unstructured":"Charych, D. et al. Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy. PLoS ONE 12, e0179431 (2017).","journal-title":"PLoS One"},{"key":"328_CR34","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1200\/JCO.2018.36.15_suppl.3006","volume":"36","author":"A Diab","year":"2018","unstructured":"Diab, A. et al. NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1\/2 results of PIVOT. J. Clin. Oncol. 36, 3006\u20133006 (2018).","journal-title":"J. Clin. Oncol."},{"key":"328_CR35","doi-asserted-by":"publisher","first-page":"e1277306","DOI":"10.1080\/2162402X.2016.1277306","volume":"6","author":"C Klein","year":"2017","unstructured":"Klein, C. et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology 6, e1277306 (2017).","journal-title":"Oncoimmunology"},{"key":"328_CR36","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1126\/science.8178155","volume":"264","author":"KH Grabstein","year":"1994","unstructured":"Grabstein, K. H. et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 264, 965\u2013968 (1994).","journal-title":"Science"},{"key":"328_CR37","doi-asserted-by":"publisher","first-page":"4940","DOI":"10.1073\/pnas.91.11.4940","volume":"91","author":"RN Bamford","year":"1994","unstructured":"Bamford, R. N. et al. The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T cell proliferation and the induction of lymphokine-activated killer cells. Proc. Natl. Acad. Sci. USA 91, 4940\u20134944 (1994).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"328_CR38","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1084\/jem.191.5.771","volume":"191","author":"MK Kennedy","year":"2000","unstructured":"Kennedy, M. K. et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 191, 771\u2013780 (2000).","journal-title":"J. Exp. Med."},{"key":"328_CR39","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1074-7613(00)80664-0","volume":"9","author":"JP Lodolce","year":"1998","unstructured":"Lodolce, J. P. et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 9, 669\u2013676 (1998).","journal-title":"Immunity"},{"key":"328_CR40","doi-asserted-by":"publisher","first-page":"49008","DOI":"10.18632\/oncotarget.10264","volume":"7","author":"M Scala Di","year":"2016","unstructured":"Di Scala, M. et al. Identification of IFN-gamma-producing T cells as the main mediators of the side effects associated to mouse interleukin-15 sustained exposure. Oncotarget 7, 49008\u201349026 (2016).","journal-title":"Oncotarget"},{"key":"328_CR41","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1006\/cimm.1997.1132","volume":"179","author":"R Evans","year":"1997","unstructured":"Evans, R., Fuller, J. A., Christianson, G., Krupke, D. M. & Troutt, A. B. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations. Cell. Immunol. 179, 66\u201373 (1997).","journal-title":"Cell. Immunol."},{"key":"328_CR42","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1073\/pnas.0307298101","volume":"101","author":"CA Klebanoff","year":"2004","unstructured":"Klebanoff, C. A. et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8(+) T cells. Proc. Natl. Acad. Sci. USA 101, 1969\u20131974 (2004).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"328_CR43","doi-asserted-by":"publisher","first-page":"5525","DOI":"10.4049\/jimmunol.1402144","volume":"193","author":"D Marshall","year":"2014","unstructured":"Marshall, D., Sinclair, C., Tung, S. & Seddon, B. Differential requirement for IL-2 and IL-15 during bifurcated development of thymic regulatory T cells. J. Immunol. 193, 5525\u20135533 (2014).","journal-title":"J. Immunol."},{"key":"328_CR44","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","volume":"33","author":"KC Conlon","year":"2015","unstructured":"Conlon, K. C. et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J. Clin. Oncol. 33, 74\u201382 (2015).","journal-title":"J. Clin. Oncol."},{"key":"328_CR45","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1158\/1078-0432.CCR-17-2451","volume":"24","author":"JS Miller","year":"2018","unstructured":"Miller, J. S. et al. A first-in-human phase i study of subcutaneous outpatient recombinant human IL15 (rhIL15) in adults with advanced solid tumors. Clin. Cancer Res. 24, 1525\u20131535 (2018).","journal-title":"Clin. Cancer Res."},{"key":"328_CR46","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1158\/0008-5472.CAN-12-2660","volume":"73","author":"MC Ochoa","year":"2013","unstructured":"Ochoa, M. C. et al. Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein. Cancer Res. 73, 139\u2013149 (2013).","journal-title":"Cancer Res."},{"key":"328_CR47","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.immuni.2007.03.006","volume":"26","author":"M Lucas","year":"2007","unstructured":"Lucas, M., Schachterle, W., Oberle, K., Aichele, P. & Diefenbach, A. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 26, 503\u2013517 (2007).","journal-title":"Immunity"},{"key":"328_CR48","doi-asserted-by":"publisher","first-page":"9166","DOI":"10.1073\/pnas.0600240103","volume":"103","author":"MP Rubinstein","year":"2006","unstructured":"Rubinstein, M. P. et al. Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc. Natl. Acad. Sci. USA 103, 9166\u20139171 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"328_CR49","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1074\/jbc.M508624200","volume":"281","author":"E Mortier","year":"2006","unstructured":"Mortier, E. et al. Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta\/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins. J. Biol. Chem. 281, 1612\u20131619 (2006).","journal-title":"J. Biol. Chem."},{"key":"328_CR50","doi-asserted-by":"publisher","first-page":"e26441","DOI":"10.4161\/onci.26441","volume":"2","author":"M Vincent","year":"2013","unstructured":"Vincent, M., Quemener, A. & Jacques, Y. Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI. Oncoimmunology 2, e26441 (2013).","journal-title":"Oncoimmunology"},{"key":"328_CR51","doi-asserted-by":"publisher","first-page":"P122","DOI":"10.1186\/2051-1426-2-S3-P122","volume":"2","author":"B Liu","year":"2014","unstructured":"Liu, B. et al. Evaluation of a novel CD20-targeted IL-15 immunotherapeutic with potent activity against B cell lymphoma. J. Immunother. Cancer 2, P122\u2013P122 (2014).","journal-title":"J. Immunother. Cancer"},{"key":"328_CR52","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2174\/156652313804806561","volume":"13","author":"MC Ochoa","year":"2013","unstructured":"Ochoa, M. C. et al. Interleukin-15 in gene therapy of cancer. Curr. Gene Ther. 13, 15\u201330 (2013).","journal-title":"Curr. Gene Ther."},{"key":"328_CR53","doi-asserted-by":"publisher","first-page":"e23410","DOI":"10.4161\/onci.23410","volume":"2","author":"MC Ochoa","year":"2013","unstructured":"Ochoa, M. C., Melero, I. & Berraondo, P. High-density lipoproteins delivering interleukin-15. Oncoimmunology 2, e23410 (2013).","journal-title":"Oncoimmunology"},{"key":"328_CR54","doi-asserted-by":"publisher","first-page":"e1393597","DOI":"10.1080\/2162402X.2017.1393597","volume":"7","author":"MC Ochoa","year":"2018","unstructured":"Ochoa, M. C. et al. Enhancement of antibody-dependent cellular cytotoxicity of cetuximab by a chimeric protein encompassing interleukin-15. Oncoimmunology 7, e1393597 (2018).","journal-title":"Oncoimmunology"},{"key":"328_CR55","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1158\/2326-6066.CIR-15-0093-T","volume":"4","author":"PR Rhode","year":"2016","unstructured":"Rhode, P. R. et al. Comparison of the superagonist complex, ALT-803, to IL15 as cancer immunotherapeutics in animal models. Cancer Immunol. Res. 4, 49\u201360 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"328_CR56","doi-asserted-by":"crossref","unstructured":"Romeem R. et al. First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood 131,2515\u20132527 (2018).","DOI":"10.1182\/blood-2017-12-823757"},{"key":"328_CR57","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S1470-2045(18)30148-7","volume":"19","author":"JM Wrangle","year":"2018","unstructured":"Wrangle, J. M. et al. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 19, 694\u2013704 (2018).","journal-title":"Lancet Oncol."},{"key":"328_CR58","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1200\/JCO.2018.36.6_suppl.510","volume":"36","author":"CJ Rosser","year":"2018","unstructured":"Rosser, C. J., Nix, J., Ferguson, L., Hernandez, L. & Wong, H. C. Phase Ib trial of ALT-803, an IL-15 superagonist, plus BCG for the treatment of BCG-na\u00efve patients with non-muscle-invasive bladder cancer. J. Clin. Oncol. 36, 510\u2013510 (2018).","journal-title":"J. Clin. Oncol."},{"key":"328_CR59","doi-asserted-by":"publisher","first-page":"5312","DOI":"10.1158\/1078-0432.CCR-10-1809","volume":"16","author":"H Schmidt","year":"2010","unstructured":"Schmidt, H. et al. Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial. Clin. Cancer Res. 16, 5312\u20135319 (2010).","journal-title":"Clin. Cancer Res."},{"key":"328_CR60","doi-asserted-by":"publisher","first-page":"5752","DOI":"10.1158\/1078-0432.CCR-12-0456","volume":"18","author":"JM Timmerman","year":"2012","unstructured":"Timmerman, J. M. et al. A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders. Clin. Cancer Res. 18, 5752\u20135760 (2012).","journal-title":"Clin. Cancer Res."},{"key":"328_CR61","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.4049\/jimmunol.175.4.2261","volume":"175","author":"Y Li","year":"2005","unstructured":"Li, Y., Bleakley, M. & Yee, C. IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J. Immunol. 175, 2261\u20132269 (2005).","journal-title":"J. Immunol."},{"key":"328_CR62","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nri2097","volume":"7","author":"A O\u2019Garra","year":"2007","unstructured":"O\u2019Garra, A. & Vieira, P. T(H)1 cells control themselves by producing interleukin-10. Nat. Rev. Immunol. 7, 425\u2013428 (2007).","journal-title":"Nat. Rev. Immunol."},{"key":"328_CR63","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.18632\/oncotarget.13736","volume":"8","author":"D Llopiz","year":"2017","unstructured":"Llopiz, D. et al. IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination. Oncotarget 8, 2659\u20132671 (2017).","journal-title":"Oncotarget"},{"key":"328_CR64","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1146\/annurev.immunol.19.1.683","volume":"19","author":"KW Moore","year":"2001","unstructured":"Moore, K. W., de Waal Malefyt, R., Coffman, R. L. & O\u2019Garra, A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19, 683\u2013765 (2001).","journal-title":"Annu. Rev. Immunol."},{"issue":"Suppl. 2","key":"328_CR65","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1440-1746.2011.07003.x","volume":"27","author":"B Gao","year":"2012","unstructured":"Gao, B. Hepatoprotective and anti-inflammatory cytokines in alcoholic liver disease. J. Gastroenterol. Hepatol. 27(Suppl. 2), 89\u201393 (2012).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"328_CR66","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jhep.2017.04.020","volume":"67","author":"J Fioravanti","year":"2017","unstructured":"Fioravanti, J. et al. Effector CD8(+) T cell-derived interleukin-10 enhances acute liver immunopathology. J. Hepatol. 67, 543\u2013548 (2017).","journal-title":"J. Hepatol."},{"key":"328_CR67","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.ccr.2011.11.003","volume":"20","author":"JB Mumm","year":"2011","unstructured":"Mumm, J. B. et al. IL-10 elicits IFNgamma-dependent tumor immune surveillance. Cancer Cell 20, 781\u2013796 (2011).","journal-title":"Cancer Cell"},{"key":"328_CR68","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1200\/JCO.2016.68.1106","volume":"34","author":"A Naing","year":"2016","unstructured":"Naing, A. et al. Safety, antitumor activity, and immune activation of pegylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors. J. Clin. Oncol. 34, 3562\u20133569 (2016).","journal-title":"J. Clin. Oncol."},{"key":"328_CR69","doi-asserted-by":"publisher","first-page":"4509","DOI":"10.1200\/JCO.2018.36.15_suppl.4509","volume":"36","author":"NM Tannir","year":"2018","unstructured":"Tannir, N. M. et al. Pegilodecakin with nivolumab (nivo) or pembrolizumab (pembro) in patients (pts) with metastatic renal cell carcinoma (RCC). J. Clin. Oncol. 36, 4509\u20134509 (2018).","journal-title":"J. Clin. Oncol."},{"key":"328_CR70","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s12016-015-8468-9","volume":"49","author":"J Choi","year":"2015","unstructured":"Choi, J., Leung, P. S., Bowlus, C. & Gershwin, M. E. IL-35 and autoimmunity: a comprehensive perspective. Clin. Rev. Allergy Immunol. 49, 327\u2013332 (2015).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"328_CR71","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2174\/156652309787909553","volume":"9","author":"P Berraondo","year":"2009","unstructured":"Berraondo, P., Prieto, J. & Gonzalez-Aseguinolaza, G. Advances in interleukin-12 gene therapy for acquired liver diseases. Curr. Gene Ther. 9, 62\u201371 (2009).","journal-title":"Curr. Gene Ther."},{"key":"328_CR72","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/j.1749-6632.1996.tb52660.x","volume":"795","author":"BL Kelsall","year":"1996","unstructured":"Kelsall, B. L., Stuber, E., Neurath, M. & Strober, W. Interleukin-12 production by dendritic cells. The role of CD40-CD40L interactions in Th1 T cell responses. Ann. N.Y. Acad. Sci. 795, 116\u2013126 (1996).","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"328_CR73","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1084\/jem.185.5.817","volume":"185","author":"SJ Szabo","year":"1997","unstructured":"Szabo, S. J., Dighe, A. S., Gubler, U. & Murphy, K. M. Regulation of the interleukin (IL)-12R beta 2 subunit expression in developing T helper 1 (Th1) and Th2 cells. J. Exp. Med. 185, 817\u2013824 (1997).","journal-title":"J. Exp. Med."},{"key":"328_CR74","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1084\/jem.194.11.1549","volume":"194","author":"S Ibe","year":"2001","unstructured":"Ibe, S., Qin, Z., Schuler, T., Preiss, S. & Blankenstein, T. Tumor rejection by disturbing tumor stroma cell interactions. J. Exp. Med. 194, 1549\u20131559 (2001).","journal-title":"J. Exp. Med."},{"key":"328_CR75","doi-asserted-by":"publisher","first-page":"807","DOI":"10.4049\/jimmunol.1001483","volume":"186","author":"J Medina-Echeverz","year":"2011","unstructured":"Medina-Echeverz, J. et al. Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J. Immunol. 186, 807\u2013815 (2011).","journal-title":"J. Immunol."},{"key":"328_CR76","doi-asserted-by":"publisher","first-page":"e28398","DOI":"10.4161\/onci.28398","volume":"3","author":"J Medina-Echeverz","year":"2014","unstructured":"Medina-Echeverz, J., Aranda, F. & Berraondo, P. Myeloid-derived cells are key targets of tumor immunotherapy. Oncoimmunology 3, e28398 (2014).","journal-title":"Oncoimmunology"},{"key":"328_CR77","doi-asserted-by":"publisher","first-page":"4677","DOI":"10.1158\/1078-0432.CCR-07-0776","volume":"13","author":"M Vecchio Del","year":"2007","unstructured":"Del Vecchio, M. et al. Interleukin-12: biological properties and clinical application. Clin. Cancer Res. 13, 4677\u20134685 (2007).","journal-title":"Clin. Cancer Res."},{"key":"328_CR78","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1172\/JCI9775","volume":"107","author":"P Romagnani","year":"2001","unstructured":"Romagnani, P. et al. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J. Clin. Investig. 107, 53\u201363 (2001).","journal-title":"J. Clin. Investig."},{"key":"328_CR79","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1084\/jem.178.4.1223","volume":"178","author":"MJ Brunda","year":"1993","unstructured":"Brunda, M. J. et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178, 1223\u20131230 (1993).","journal-title":"J. Exp. Med."},{"key":"328_CR80","first-page":"2541","volume":"90","author":"JP Leonard","year":"1997","unstructured":"Leonard, J. P. et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90, 2541\u20132548 (1997).","journal-title":"Blood"},{"key":"328_CR81","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1158\/2326-6066.CIR-14-0216","volume":"3","author":"JI Quetglas","year":"2015","unstructured":"Quetglas, J. I. et al. Virotherapy with a Semliki Forest virus-based vector encoding IL12 synergizes with PD-1\/PD-L1 blockade. Cancer Immunol. Res. 3, 449\u2013454 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"328_CR82","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/cgt.2009.45","volume":"17","author":"M Rodrigo-Garzon","year":"2010","unstructured":"Rodrigo-Garzon, M., Berraondo, P., Ochoa, L., Zulueta, J. J. & Gonzalez-Aseguinolaza, G. Antitumoral efficacy of DNA nanoparticles in murine models of lung cancer and pulmonary metastasis. Cancer Gene Ther. 17, 20\u201327 (2010).","journal-title":"Cancer Gene Ther."},{"key":"328_CR83","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1006\/mthe.2002.0601","volume":"5","author":"ML Lucas","year":"2002","unstructured":"Lucas, M. L., Heller, L., Coppola, D. & Heller, R. IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol. Ther. 5, 668\u2013675 (2002).","journal-title":"Mol. Ther."},{"key":"328_CR84","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.18632\/oncotarget.1853","volume":"5","author":"J Fallon","year":"2014","unstructured":"Fallon, J. et al. The immunocytokine NHS-IL12 as a potential cancer therapeutic. Oncotarget 5, 1869\u20131884 (2014).","journal-title":"Oncotarget"},{"key":"328_CR85","doi-asserted-by":"publisher","first-page":"4746","DOI":"10.1172\/JCI58814","volume":"121","author":"SP Kerkar","year":"2011","unstructured":"Kerkar, S. P. et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J. Clin. Investig. 121, 4746\u20134757 (2011).","journal-title":"J. Clin. Investig."},{"key":"328_CR86","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-14-2085","volume":"21","author":"L Zhang","year":"2015","unstructured":"Zhang, L. et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin. Cancer Res. 21, 2278\u20132288 (2015).","journal-title":"Clin. Cancer Res."},{"key":"328_CR87","doi-asserted-by":"publisher","first-page":"5896","DOI":"10.1200\/JCO.2007.15.6794","volume":"26","author":"AI Daud","year":"2008","unstructured":"Daud, A. I. et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J. Clin. Oncol. 26, 5896\u20135903 (2008).","journal-title":"J. Clin. Oncol."},{"key":"328_CR88","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1001\/jama.2014.13943","volume":"312","author":"FS Hodi","year":"2014","unstructured":"Hodi, F. S. et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. Jama 312, 1744\u20131753 (2014).","journal-title":"Jama"},{"key":"328_CR89","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka, R. H. et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33, 2780\u20132788 (2015).","journal-title":"J. Clin. Oncol."},{"key":"328_CR90","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1200\/JCO.2014.57.4244","volume":"33","author":"DT Le","year":"2015","unstructured":"Le, D. T. et al. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J. Clin. Oncol. 33, 1325\u20131333 (2015).","journal-title":"J. Clin. Oncol."},{"key":"328_CR91","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/CJI.0b013e31829fb7a2","volume":"36","author":"DT Le","year":"2013","unstructured":"Le, D. T. et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J. Immunother. 36, 382\u2013389 (2013).","journal-title":"J. Immunother."},{"key":"328_CR92","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/nrd1175","volume":"2","author":"MA Palladino","year":"2003","unstructured":"Palladino, M. A., Bahjat, F. R., Theodorakis, E. A. & Moldawer, L. L. Anti-TNF-alpha therapies: the next generation. Nat. Rev. Drug Discov. 2, 736\u2013746 (2003).","journal-title":"Nat. Rev. Drug Discov."},{"key":"328_CR93","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/sj.bjc.6600479","volume":"87","author":"L Zhao","year":"2002","unstructured":"Zhao, L., Ching, L. M., Kestell, P. & Baguley, B. C. The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. Br. J. Cancer 87, 465\u2013470 (2002).","journal-title":"Br. J. Cancer"},{"key":"328_CR94","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1634\/theoncologist.11-4-397","volume":"11","author":"R Horssen van","year":"2006","unstructured":"van Horssen, R., Ten Hagen, T. L. & Eggermont, A. M. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 11, 397\u2013408 (2006).","journal-title":"Oncologist"},{"key":"328_CR95","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/377348a0","volume":"377","author":"L Zheng","year":"1995","unstructured":"Zheng, L. et al. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 377, 348\u2013351 (1995).","journal-title":"Nature"},{"key":"328_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02358-7","volume":"8","author":"F Bertrand","year":"2017","unstructured":"Bertrand, F. et al. TNFalpha blockade overcomes resistance to anti-PD-1 in experimental melanoma. Nat. Commun. 8, 2256 (2017).","journal-title":"Nat. Commun."},{"key":"328_CR97","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2008.07.001","volume":"134","author":"J Massague","year":"2008","unstructured":"Massague, J. TGFbeta in cancer. Cell 134, 215\u2013230 (2008).","journal-title":"Cell"},{"key":"328_CR98","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/nrd3810","volume":"11","author":"RJ Akhurst","year":"2012","unstructured":"Akhurst, R. J. & Hata, A. Targeting the TGFbeta signalling pathway in disease. Nat. Rev. Drug Discov. 11, 790\u2013811 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"328_CR99","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature25492","volume":"554","author":"DVF Tauriello","year":"2018","unstructured":"Tauriello, D. V. F. et al. TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 554, 538\u2013543 (2018).","journal-title":"Nature"},{"key":"328_CR100","doi-asserted-by":"publisher","first-page":"e1426519","DOI":"10.1080\/2162402X.2018.1426519","volume":"7","author":"KM Knudson","year":"2018","unstructured":"Knudson, K. M. et al. M7824, a novel bifunctional anti-PD-L1\/TGFbeta Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine. Oncoimmunology 7, e1426519 (2018).","journal-title":"Oncoimmunology"},{"key":"328_CR101","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1158\/0008-5472.CAN-14-3511","volume":"75","author":"C Vanpouille-Box","year":"2015","unstructured":"Vanpouille-Box, C. et al. TGFbeta Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. Cancer Res. 75, 2232\u20132242 (2015).","journal-title":"Cancer Res."},{"key":"328_CR102","unstructured":"Formenti, S. C. et al. Focal irradiation and systemic TGFbeta blockade in metastatic breast cancer. Clin. Cancer Res. 24, 2493\u20132504 (2018)"},{"key":"328_CR103","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature07205","volume":"454","author":"A Mantovani","year":"2008","unstructured":"Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature 454, 436\u2013444 (2008).","journal-title":"Nature"},{"key":"328_CR104","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.3337","volume":"19","author":"SM Pyonteck","year":"2013","unstructured":"Pyonteck, S. M. et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19, 1264\u20131272 (2013).","journal-title":"Nat. Med."},{"key":"328_CR105","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","volume":"25","author":"CH Ries","year":"2014","unstructured":"Ries, C. H. et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 25, 846\u2013859 (2014).","journal-title":"Cancer Cell"},{"key":"328_CR106","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.phrs.2015.08.004","volume":"100","author":"T Kitamura","year":"2015","unstructured":"Kitamura, T. & Pollard, J. W. Therapeutic potential of chemokine signal inhibition for metastatic breast cancer. Pharmacol. Res. 100, 266\u2013270 (2015).","journal-title":"Pharmacol. Res."},{"key":"328_CR107","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1093\/annonc\/mdx190","volume":"28","author":"MF Sanmamed","year":"2017","unstructured":"Sanmamed, M. F. et al. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. Ann. Oncol. 28, 1988\u20131995 (2017).","journal-title":"Ann. Oncol."},{"key":"328_CR108","doi-asserted-by":"publisher","first-page":"e94296","DOI":"10.1172\/jci.insight.94296","volume":"2","author":"C Dominguez","year":"2017","unstructured":"Dominguez, C., McCampbell, K. K., David, J. M. & Palena, C. Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer. JCI Insight 2, e94296 (2017).","journal-title":"JCI Insight"},{"key":"328_CR109","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ctrv.2017.08.004","volume":"60","author":"C Alfaro","year":"2017","unstructured":"Alfaro, C. et al. Interleukin-8 in cancer pathogenesis, treatment and follow-up. Cancer Treat. Rev. 60, 24\u201331 (2017).","journal-title":"Cancer Treat. Rev."},{"key":"328_CR110","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1189\/jlb.1009671","volume":"88","author":"Q Zhao","year":"2010","unstructured":"Zhao, Q. Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases. J. Leukoc. Biol. 88, 41\u201355 (2010).","journal-title":"J. Leukoc. Biol."},{"key":"328_CR111","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/fonc.2015.00202","volume":"5","author":"PA Ott","year":"2015","unstructured":"Ott, P. A., Hodi, F. S. & Buchbinder, E. I. Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data. Front. Oncol. 5, 202 (2015).","journal-title":"Front. Oncol."},{"key":"328_CR112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/annonc\/mdw630","volume":"28","author":"T Powles","year":"2017","unstructured":"Powles, T. et al. IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC). Ann. Oncol. 28, 1 (2017).","journal-title":"Ann. Oncol."},{"key":"328_CR113","doi-asserted-by":"publisher","first-page":"9002","DOI":"10.1200\/JCO.2018.36.15_suppl.9002","volume":"36","author":"MA Socinski","year":"2018","unstructured":"Socinski, M. A. et al. Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo)+chemotherapy (chemo)\u00b1bevacizumab (bev) vs chemo+bev in 1L nonsquamous (NSQ) NSCLC. J. Clin. Oncol. 36, 9002\u20139002 (2018).","journal-title":"J. Clin. Oncol."},{"key":"328_CR114","doi-asserted-by":"crossref","unstructured":"Stein, S.et al. Safety and clinical activity of 1L atezolizumab+bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC). J. Clin. Oncol. 36, 4074\u20134074 .","DOI":"10.1200\/JCO.2018.36.15_suppl.4074"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0328-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0328-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0328-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:03:44Z","timestamp":1684602224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-018-0328-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,9]]},"references-count":114,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["328"],"URL":"https:\/\/doi.org\/10.1038\/s41416-018-0328-y","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,9]]},"assertion":[{"value":"19 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.M. is a consultant for Bristol Myers Squibb, Roche-Genentech, MedImmune, Merck Serono, Bioncotech, F-STAR, Genemab and Tusk. He receives grants from Bristol Myers Squibb, Roche-Genentech, and Alligator. J.L.P.-G. is an advisor to Bristol Myers, Roche-Genentech and Servier. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Note"}}]}}